ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES HOW INCENTIVES COULD SUPPORT EFFECTIVENESS RESEARCH OF MEDICAL DEVICES

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held a workshop this morning on Incentivizing Research Into the Effectiveness of Medical Devices at the Society’s 19th Annual European Congress in Vienna, Austria.  The session was moderated by Rosanna Tarricone, PhD, Professor, Centre for Research on Health and Social Care Management, Bocconi University, Milan, Italy. Speakers for the session included:
  • Michael F. Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
  • Mirella Marlow, MBA, MA, Programme Director, Devices and Diagnostics Systems, National Institute for Health and Clinical Excellence (NICE), London, UK
  • Adrian Griffin, MSc, Vice President, HTA and Reimbursement Policy, Johnson & Johnson, High Wycombe, UK
This issue panel examined how incentives could be utilized to increase the range and quality of effectiveness research of medical devices. Speakers noted that medical devices often gain market authorization with significantly less clinical effectiveness evidence than other health technologies, such as pharmaceuticals, because of the different legal requirements for approval of medical devices. The panel also remarked that post-market effectiveness research may actually be more important for medical devices than pharmaceuticals since the performance of the device often depends on the interaction with the user. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×